NASDAQ · Healthcare
Invest in Biodexa Pharmaceuticals stock from India
Indian and foreign residents can buy Biodexa Pharmaceuticals (BDRX) shares directly through Paasa.
By Paasa · Updated
Biodexa Pharmaceuticals at a glance
- Price
- $0.66+$0.01 (1.71%)
- Market cap
- $489.52K
- Day range
- $0.63 – $0.66
- P/E
- -0.01
- Dividend yield
- None
- Volume
- 147.17K
- 1 month
- -19.17%
- 6 months
- -78.77%
- YTD
- -94.22%
- 1 year
- -98.03%
- 5 years
- -100.00%
Biodexa Pharmaceuticals statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | £0.0 | £0.0 | £381.0K | £699.0K | £578.0K |
| Gross profit | −£184.9K | −£5.4M | −£3.7M | −£4.4M | −£4.1M |
| Operating income | −£8.3M | −£9.2M | −£8.0M | −£8.9M | −£7.0M |
| Net income | −£6.2M | −£5.7M | −£7.1M | −£7.7M | −£5.5M |
| Earnings per share | −£400.00 | −£3,705.65 | −£69,640.00 | −£4,770,680.00 | −£4,661,590.00 |
| EBITDA | −£8.1M | −£9.1M | −£7.2M | −£8.3M | −£5.7M |
| Total assets | £18.1M | £14.8M | £10.5M | £5.5M | £12.9M |
| Total debt | £60.9K | £727.0K | £464.0K | £624.0K | £766.0K |
| Cash and short-term investments | £8.5M | £1.7M | £6.0M | £2.8M | £10.1M |
| Shareholders' equity | £11.4M | £8.3M | £4.7M | £3.2M | £10.5M |
| Operating cash flow | −£5.4M | −£12.3M | −£6.8M | −£7.0M | −£6.0M |
| Free cash flow | −£5.4M | −£13.0M | −£7.1M | −£7.1M | −£6.3M |
| Capital expenditure | −£2.0K | −£774.0K | −£263.0K | −£62.0K | −£320.0K |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in GBP; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Estrella Immunopharma | ESLA | $0.47 | $19.91M |
| Kazia Therapeutics Ltd ADR | KZIA | $9.60 | $15.54M |
| BioVie | BIVI | $1.52 | $11.46M |
| CNS Pharmaceuticals | CNSP | $5.30 | $7.75M |
| InMed Pharmaceuticals | INM | $1.36 | $7.47M |
| Galmed Pharmaceuticals | GLMD | $4.63 | $4.78M |
| GRI Bio | GRI | $1.93 | $4.22M |
| Can-Fite BioPharma | CANF | $2.20 | $2.88M |
Peers as grouped by the data provider. This is not an investment recommendation.
How to invest in Biodexa Pharmaceuticals from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit.
Step 3
Search BDRX and buy
Find Biodexa Pharmaceuticals by name or by its ticker, BDRX, and place your order. Fractional shares are available and there is no minimum trade size, so you can buy by amount instead of whole shares.
Why invest in Biodexa Pharmaceuticals from India
What Biodexa Pharmaceuticals does
Biodexa Pharmaceuticals Plc, a biopharmaceutical company in the clinical development stage, is dedicated to advancing a diverse portfolio of products. Founded in 2000 and headquartered in Cardiff, United Kingdom, the company was formerly known as Midatech Pharma plc until its rebranding in March 2023. Biodexa Pharmaceuticals operates in the Biotechnology industry within the Healthcare sector.
Hold a dollar asset
Biodexa Pharmaceuticals shares are priced in US dollars, so a weaker rupee adds to what they're worth in rupees. The rupee depreciated over 85% against the dollar between 2010 and 2025.
Buy a fraction of a share
Buy by amount, not by share, and get the matching fraction of one Biodexa Pharmaceuticals share. There is no minimum trade size.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy Biodexa Pharmaceuticals stock from India?
Yes. Indian residents and NRIs can buy Biodexa Pharmaceuticals (BDRX) shares directly through Paasa. Biodexa Pharmaceuticals is listed on NASDAQ, in the Biotechnology industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
Do I need to buy a full Biodexa Pharmaceuticals share?
No. You can buy part of one Biodexa Pharmaceuticals share and add to your position over time. One share is $0.66, and you can buy whole shares or any fraction; there is no minimum trade size.
How are Biodexa Pharmaceuticals dividends taxed for Indian investors?
Biodexa Pharmaceuticals trades on NASDAQ but is domiciled in United Kingdom, so any withholding on its dividends follows that country's rules rather than those of the US. What trades there is a depositary receipt over Biodexa Pharmaceuticals shares rather than the ordinary share itself. Some non-US companies list in the US through American Depositary Receipts, which can carry dividend withholding at the company's home-country rate. Dividends are taxed at your slab rate in India. Paasa's dividend report shows the gross amount and any tax withheld for each payment.
What tax do I pay in India when I sell Biodexa Pharmaceuticals shares?
The US does not levy capital gains tax on shares for Indian residents. In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the USD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.